Background: Liver transplantation for hepatic tumours is known as a proven treatment opportunity. The outcome has improved over the past decades because of the appropriate recipient selection.
Introduction
Liver transplantation (OLT) is a well-established and durable surgical therapy for all forms of end-stage liver disease and for certain malignancies. Over the years, the liver transplant survival rate improved, Adam R. et al. [1] descibed a 1-and 5-year survival of 83% and 75%, respectively. Th e success of such treatment has resulted in a progressively increasing claim for liver transplantation. At the same time, the organ donor shortage is rising. Several strategies have been established to increase the number of liver transplantation, such as harvesting organs from nonheart-beating donors and live donors, liver splitting and using organs from expanded criteria donors.
Liver transplantation is the best treatment option for patients with hepatocellular carcinoma and liver cirrhosis, unless they have excellent liver function and minimal portal hypertension [2] . Early experience of liver transplantation for patients with hepatocellular carcinoma was poor because tumoral recurrence was very frequent [3] . In 1996, Mazzaferro et al. [4] showed that a subgroup of patients with radiologic evidence of a single tumor ≤5 cm in diameter, or two to three tumors ≤3 cm in diameter had 5-year and recurrence-free survival rates of 75 and 83%, respectively. Th e Milan criteria were subsequently adopted by the United Network for Organ Sharing (UNOS) staging system for allocating organs for liver transplantation in the United States. However, recent data suggest that Milan criteria may be too conservative. Yao et al. [5] reported their results with a moderate expansion of these criteria (the socalled University of California at San Francisco (UCSF) criteria). Patients selected with these expanded criteria had disease-free survival that was comparable to survival of patients selected with Milan criteria.
In Hungary the fi rst liver transplantations were performed in 1995 in the Department of Transplantation and Surgery of the Semmelweis University, Budapest. In the case of hepatocellular carcinoma, from 2001 we started to adapt our policies to the Milan criteria, and our results are acceptable and comparable to the worldwide results. Th e 5-year survival after OLT for HCC is more than 50% comparing to the more than 80% 5-year survival rate after OLT for other indications [6] . In this review the author analyzes the survival results of an ongoing study of liver transplantation for hepatocellular carcinoma between 1 January 2004 and 1 January 2011. Our aim is to fi nd the possible ways to improve patient survival by refi ning recipient selection and tailoring individual immunosuppressive therapy.
Material and method
A single-institution study of 29 consecutive adult patients undergoing orthotopic liver transplantation between 1 January 2004 and 1 January 2011 with the indication of hepatocellular carcinoma. Survival was calculated with Kaplan-Meyer log rank analysis. Mean age at time of transplantation was 50.8 years (28-63). Th e median follow-up was 1236.3 days (89-2266). 55.17% of the recipients were male (n = 16) and 44.82% were female (n = 13). All surgeons used similar "cross-clamp" technique (recipient hepatectomy including vena cava segment). Th e histological examinations are under investigation regarding tumour
Correspondence to: László Piros E-mail: pirosl666@hotmail.com size, grade, vessel invasion and extrahepatic propagation. Th e average intraoperative demand for blood transfusion was 5.8 units (0-26). All of the liver transplant recipients received a maintenance immunosuppressive therapy combination of tacrolimus or cyclosporine A, mycophenolatemofetil (MMF) and corticosteroids. In the case of tumour recurrency, the immunosuppresion was converted into an mTOR-inhibitor (sirolimus or everolimus).
Results
Survival was calculated with Kaplan-Meyer log rank analysis ( Figure 1) . Nine of our patients died in the late postoperative period (31.0%). Th e main cause of death was HCC recurrency, in 6 cases: 3 in the liver, 1 in the lung, 1 in the cardia and 1 in the femur were observed. 2 patients died because of HCV recurrency and 1 with liver angiosarcoma. Th e 1-year survival was 85.7% and the 3-year survival was 71.7%. According to the histology fi fteen patients were within the Milan criteria and 14 exceeded the criteria.
Discussion
While patients with early resectable HCC and preserved hepatic function should undergo surgical resection, in those with unresectable disease due to underlying liver dysfunction, orthotopic liver transplantation off ers the best chance for cure. Liver transplantation for hepatic tumours is known as a proven treatment opportunity. Th e fi rst results were unsatisfactory and showed that only a highly selected patient population would benefi t from transplantation. According to the United Network for Organ Sharing database, the 5-year survival of liver transplantation for hepatocellular carcinoma (HCC) was only 25% in the end of the 1980's, but the outcome has improved over the past decades because of the appropriate recipient selection. [7] According to Hoti et al. [8] , currently, 15% of all liver transplants are performed for hepatocellular carcinoma. Liver transplantation for HCC in the adult population ends in good results for patients whose tumour masses do not exceed the Milan criteria. In patients with small HCC at an early stage and preserved liver function, liver resection is an alternative method. Liver resection may present similar short term survival results to orthotopic liver transplantation (OLT), and avoids the long-term adverse eff ects of immunosuppression. However, liver transplantation is associated with longer disease-free survival in well-compensated cirrhotic patients with early stage hepatocellular carcinoma [9] .
Cholangiocarcinoma treated by aggressive combination of chemo-and radiotherapy after transplantation showes lower, but promising results. Results of OLT are excellent in paediatric patients with unresecable and/or recurrent hepatoblastoma. Epithelioid hemangioendothelioma is also an indication, even in the presence of extrahepatic propagation. Angiosarcoma is associated with very poor survival and considered as a contraindication. Liver transplantation for metastatic liver disease from neuroendocrine tumours can result in long-term survival. Transplantation for colorectal liver metastases is currently contraindicated after the poor outcomes in the 1990's, but requires further re-evaluation according to the overall improvement in liver transplantation by at least 20% [10] .
Th e treatment of hepatocellular carcinoma by liver transplantation has changed signifi cantly in the last two decades. Introduction of measure criteria -such as the Milan or UCSF-expanded criteria -and the proper recipient selection have led to satisfying survival, but it is necessary to achieve better results. Th e role of interventional radiological methods, such as chemoembolisation and radiofrequency ablation in bridging and down-staging modalities is prominent [11, 12] .
Expanding the HCC criteria for OLT allows more recipients to be eligible for transplantation, but there are also arguments against it because of the increased risk of vascular invasion and tumour recurrence at higher stages of HCC. Th e most important limitation of OLT for HCC is the shortage of deceased donors and so the liver grafts, and the development of living donor liver transplantation could be a solution for this donor shortage [13] .
Our results with the 1-and 3-year survival rates -85.7% and 71.7% respectively -are comparable to other's in the literature. Herrero et al. [14] reported a 1-, 3-, 5-, 7-, and 10-year survival rates of their 73 transplanted HCC patients were 86%, 74%, 70%, 61%, and 50%, respectively. Similarly their patients exceeding Milan criteria had a higher dropout rate due to tumoral progression. According to a large multicenter study by Mazzaferro et al. [15] for those transplanted outside the Milan criteria, 5-year overall survival was 53.6% compared with 73.3% for those that met the criteria.
Another very important issue is the eff ective immunosuppression therapy by using drugs that help to decrease HCC recurrence. Introduction of mTOR-inhibitors to the immunosuppressive therapy protocols guided to lower tumour incidence among transplant patients in general [16] . Coadministration of sorafenib and an mTOR in- hibitor could be eff ective in patients with posttransplant HCC recurrence not suitable for radical therapy, but the toxicity and effi cacy need to be further evaluated [17] . In our department we are trying to fi nd mTOR activity in the HCC, normal and cirrhotic liver biopsies to evaluate the potential effi cacy of our immunosuppressive strategy. Asian transplant centers have signifi cantly modifi ed the previous restrictions with the use of biomarker des-carboxy-prothrombin [18] . Th ese strategies should help to improve better outcomes of liver transplantation for malignancies in the future.
Conclusion
Further investigations are needed on the fi eld of histological and biological attributes of the hepatocellular carcinoma. Our aim is to fi nd a better and individualized immunosuppressive protocol, wich is not only protective against acute rejection of the transplanted organ, but also protective against recurrency or de novo manifestation of malignancy. Moreover it is important to expand the liver donor pool by developing the living donor liver transplant program.
